Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabel Miras

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Therapeutic Advances in Medical Oncology|December 30, 2024
Predictive factors for complete pathologic response in luminal breast cancer: impact of ki67 and HER2 low expressionIsabel Miras, Ana Gil, Marta Benavent, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2025
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group TrialXavier Garcia-Del-Muro, Begoña P Valderrama, Ana Medina-Colmenero, et al.
BJC Reports|November 8, 2024
Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational studyChantal F Stockem, Sarah M H Einerhand, Isabel Miras Rodríguez, et al.
The Pediatric Infectious Disease Journal|April 10, 2026
Incidence and Clinical Characteristics of Hemorrhagic Manifestations in Children With Influenza: A Multicenter Retrospective StudyMiguel Ángel Molina Gutiérrez, María Ángeles García Herrero, María García de Oteyza, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Therapeutic Advances in Medical Oncology|December 30, 2024
Predictive factors for complete pathologic response in luminal breast cancer: impact of ki67 and HER2 low expressionIsabel Miras, Ana Gil, Marta Benavent, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2025
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group TrialXavier Garcia-Del-Muro, Begoña P Valderrama, Ana Medina-Colmenero, et al.
BJC Reports|November 8, 2024
Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational studyChantal F Stockem, Sarah M H Einerhand, Isabel Miras Rodríguez, et al.
The Pediatric Infectious Disease Journal|April 10, 2026
Incidence and Clinical Characteristics of Hemorrhagic Manifestations in Children With Influenza: A Multicenter Retrospective StudyMiguel Ángel Molina Gutiérrez, María Ángeles García Herrero, María García de Oteyza, et al.
Pageof 2